Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis.

Niho S, Yamanaka T, Umemura S, Matsumoto S, Yoh K, Goto K, Ohmatsu H, Ohe Y.

Jpn J Clin Oncol. 2013 Apr;43(4):390-5. doi: 10.1093/jjco/hyt020. Epub 2013 Feb 26.

PMID:
23444114
2.

Innovator and generic cisplatin formulations: comparison of renal toxicity.

Sekine I, Kubota K, Tamura Y, Asahina H, Yamada K, Horinouchi H, Nokihara H, Yamamoto N, Tamura T.

Cancer Sci. 2011 Jan;102(1):162-5. doi: 10.1111/j.1349-7006.2010.01764.x. Epub 2010 Nov 5.

3.

[Evaluation of the Safety of a Generic Formulation of Cisplatin in Patients with Thoracic Malignancies].

Ueda Y, Kondo Y, Suzuki H, Okamoto N, Morishita N, Tamiya M, Shiroyama T, Kumode A, Usui N, Nakano H, Sando M, Tanaka E, Hirashima T.

Gan To Kagaku Ryoho. 2015 Jul;42(7):827-32. Japanese.

PMID:
26197744
4.

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation.

Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, Yamagishi T, Kubo T, Tanimoto M, Kiura K, Takigawa N.

Drug Des Devel Ther. 2014 Dec 3;8:2401-8. doi: 10.2147/DDDT.S71419. eCollection 2014.

5.

Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.

Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y.

Jpn J Clin Oncol. 2014 Apr;44(4):346-54. doi: 10.1093/jjco/hyu004. Epub 2014 Feb 5.

PMID:
24503028
6.

Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.

Spence MM, Nguyen LM, Hui RL, Chan J.

Pharmacotherapy. 2012 Nov;32(11):981-7. doi: 10.1002/phar.1130. Epub 2012 Oct 16.

PMID:
23074134
7.

Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.

Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A.

Tumori. 2007 Mar-Apr;93(2):138-44.

8.

Renal tolerance to cisplatin in patients 70 years and older.

Cubillo A, Cornide M, López JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordoñez A, González Barón M.

Am J Clin Oncol. 2001 Apr;24(2):192-7.

PMID:
11319297
9.

[Frequency of decreased renal function between patients treated with brand and generic products of vancomycin hydrochloride injection].

Izuwa Y, Ueshima S, Sato T, Okazaki M, Aiba T, Kawasaki H, Kurosaki Y, Sendo T.

Yakugaku Zasshi. 2008 Oct;128(10):1493-8. Japanese.

10.

Serum creatinine and cholesterol levels of testicular cancer patients in long-term follow up.

Hisamatsu E, Kawai K, Hinotsu S, Miyanaga N, Shimazui T, Akaza H.

Int J Urol. 2005 Aug;12(8):751-6.

11.

Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity.

Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T.

Cancer Sci. 2007 Sep;98(9):1408-12. Epub 2007 Jun 26.

12.
13.

The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.

Unterecker S, Proft F, Riederer P, Lauer M, Deckert J, Pfuhlmann B.

Ther Drug Monit. 2014 Apr;36(2):269-72. doi: 10.1097/FTD.0000000000000008.

PMID:
24365982
14.

The role of the renin-angiotensin system in cisplatin nephrotoxicity.

Deegan PM, Nolan C, Ryan MP, Basinger MA, Jones MM, Hande KR.

Ren Fail. 1995 Nov;17(6):665-74.

PMID:
8771239
15.

Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy.

Oike T, Ohno T, Noda SE, Sato H, Tamaki T, Kiyohara H, Ando K, Nakano T.

J Radiat Res. 2013 May;54(3):474-8. doi: 10.1093/jrr/rrs121. Epub 2012 Dec 14.

16.

[Amifostine as protective agent in cisplatin-based chemotherapy of advanced bladder cancer].

Heidenreich A, Marx FJ, Peters HJ.

Urologe A. 1999 Nov;38(6):586-91. German.

PMID:
10591805
17.

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.

Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R.

Cancer Chemother Pharmacol. 1997;40(4):293-308.

PMID:
9225947
18.
19.

Cisplatin-induced vomiting depends on circadian timing.

Kobayashi M, To H, Tokue A, Fujimura A, Kobayashi E.

Chronobiol Int. 2001 Sep;18(5):851-63.

PMID:
11763992
20.

Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.

Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z, Turner N.

Toxicol Sci. 1998 Nov;46(1):155-65.

PMID:
9928679

Supplemental Content

Support Center